EDAP TMS SA
Close on Oct 19, 2026
About Edap Tms
Electromedical & Electrotherapeutic Apparatus, SIC 3845
EDAP TMS S.A. develops, manufactures, and markets non-invasive therapeutic ultrasound and energy-based medical devices. Its core operations center on High Intensity Focused Ultrasound (HIFU) technology, featuring the Focal One robotic system for the ablation of prostate tissue. The company also offers legacy urology products, such as extracorporeal shock wave lithotripsy systems, related consumables, maintenance services, and distributed third-party medical equipment. Its primary customers are urologists and gynecologists operating within public, private, and academic hospitals as well as clinics.
The company is headquartered in Vaulx-en-Velin, France, and operates globally across the United States, Europe, Asia, and other international territories. It maintains a direct sales force in the United States, France, Germany, the United Kingdom, Switzerland, Scandinavia, Malaysia, and South Korea. In addition, it distributes legacy products directly in Japan, South Korea, and Malaysia, while serving healthcare providers across Latin America, the Middle East, and wider Asia through independent distribution partners.
Summary of the business section of Edap Tms's latest annual report, written by StockData.
Company profile
Company
- Legal name
- EDAP TMS SA
- Founded
- 1979
- Headquarters
- 69120 Vaulx En Velin, I0
- Address
- Parc D'Activites La Poudrette Lamartine, 4 Rue Du Dauphine 69120
- Phone
- 33672643508
- Employees
- 289, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Fiscal year ends
- December 31
- Auditor
- KPMG S.A., Lyon, France
Stock & identifiers
- Ticker
- FOCL
- Exchange
- Nasdaq
- Shares outstanding
- 38M, Aug 14, 2026
- Public float
- $61.85M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1041934
- CUSIP
- 268311107
- ISIN
- US2683111072
- LEI
- 9695007G9BC43P81WC36
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ryan Rhodes | Chief Executive Officer, Director | 626,649 |
| Steven Annen | SVP, Marketing & Product Mgmt. | 136,490 |
| Sanket Shah | General Counsel & Corp Sec | 72,500 |
| Kenneth S. Mobeck | Chief Financial Officer | 181,610 |
| Francois Mattieu Dietsch | Chief Accounting Officer | 12,000 |
| David R. Horn | Director | 10,000 |
| Fran Schulz | Director | 15,100 |
| Joshua Levine | Director | 45,000 |
| Lance Willsey | Director | 1,291,780 |
| Glendon E. French III | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Rhodes | $1.74M | $2.66M | $860.48K | $62 | – |
| FY2024 Mr. Rhodes | $1.28M | $768.59K | $738.07K | $42 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 289 employees worldwide, with approximately 24% based in the United States and the remainder located internationally.”